Abstract

Introduction: Tamoxifen is a selective estrogen receptor modulator used widely for the treatment of breast cancer. Apart from its common adverse reactions such as endometrial cancer, deep vein thrombosis, pulmonary emboli, there are very few reports about its ability to cause vasculitis. Case report: A 45-year-old woman who underwent modified radical mastectomy was started on tamoxifen. Six months later, she developed vasculitis which was confirmed by immunofluorescence-induced vasculitis in a pre-menopausal woman. Management and outcome: Dapsone was used to relieve her symptoms for two weeks, but the lesions reappeared when dapsone was stopped. She continues to suffer from vasculitis as tamoxifen could not be discontinued. Discussion: This case report is important in order to draw attention towards this rare, but equally severe side effect of cutaneous vasculitis due to the most commonly used drug for breast cancer. In view of the absence of alternative medications for pre-menopausal women, it is necessary to have a strict monitoring of its adverse effects as well as more intensive research for a better agent.

Original languageEnglish
JournalJournal of Oncology Pharmacy Practice
DOIs
Publication statusAccepted/In press - 01-01-2019

Fingerprint

Tamoxifen
Vasculitis
Dapsone
Breast Neoplasms
Modified Radical Mastectomy
Selective Estrogen Receptor Modulators
Endometrial Neoplasms
Embolism
Venous Thrombosis
Fluorescent Antibody Technique
Lung
Skin
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{533d905d50d649d4baa4905fb222a0bd,
title = "Tamoxifen-induced vasculitis",
abstract = "Introduction: Tamoxifen is a selective estrogen receptor modulator used widely for the treatment of breast cancer. Apart from its common adverse reactions such as endometrial cancer, deep vein thrombosis, pulmonary emboli, there are very few reports about its ability to cause vasculitis. Case report: A 45-year-old woman who underwent modified radical mastectomy was started on tamoxifen. Six months later, she developed vasculitis which was confirmed by immunofluorescence-induced vasculitis in a pre-menopausal woman. Management and outcome: Dapsone was used to relieve her symptoms for two weeks, but the lesions reappeared when dapsone was stopped. She continues to suffer from vasculitis as tamoxifen could not be discontinued. Discussion: This case report is important in order to draw attention towards this rare, but equally severe side effect of cutaneous vasculitis due to the most commonly used drug for breast cancer. In view of the absence of alternative medications for pre-menopausal women, it is necessary to have a strict monitoring of its adverse effects as well as more intensive research for a better agent.",
author = "Utkarsha Kulkarni and Veena Nayak and Prabhu, {Mukhyaprana M.} and Raghavendra Rao",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1078155219862342",
language = "English",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",

}

Tamoxifen-induced vasculitis. / Kulkarni, Utkarsha; Nayak, Veena; Prabhu, Mukhyaprana M.; Rao, Raghavendra.

In: Journal of Oncology Pharmacy Practice, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tamoxifen-induced vasculitis

AU - Kulkarni, Utkarsha

AU - Nayak, Veena

AU - Prabhu, Mukhyaprana M.

AU - Rao, Raghavendra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Tamoxifen is a selective estrogen receptor modulator used widely for the treatment of breast cancer. Apart from its common adverse reactions such as endometrial cancer, deep vein thrombosis, pulmonary emboli, there are very few reports about its ability to cause vasculitis. Case report: A 45-year-old woman who underwent modified radical mastectomy was started on tamoxifen. Six months later, she developed vasculitis which was confirmed by immunofluorescence-induced vasculitis in a pre-menopausal woman. Management and outcome: Dapsone was used to relieve her symptoms for two weeks, but the lesions reappeared when dapsone was stopped. She continues to suffer from vasculitis as tamoxifen could not be discontinued. Discussion: This case report is important in order to draw attention towards this rare, but equally severe side effect of cutaneous vasculitis due to the most commonly used drug for breast cancer. In view of the absence of alternative medications for pre-menopausal women, it is necessary to have a strict monitoring of its adverse effects as well as more intensive research for a better agent.

AB - Introduction: Tamoxifen is a selective estrogen receptor modulator used widely for the treatment of breast cancer. Apart from its common adverse reactions such as endometrial cancer, deep vein thrombosis, pulmonary emboli, there are very few reports about its ability to cause vasculitis. Case report: A 45-year-old woman who underwent modified radical mastectomy was started on tamoxifen. Six months later, she developed vasculitis which was confirmed by immunofluorescence-induced vasculitis in a pre-menopausal woman. Management and outcome: Dapsone was used to relieve her symptoms for two weeks, but the lesions reappeared when dapsone was stopped. She continues to suffer from vasculitis as tamoxifen could not be discontinued. Discussion: This case report is important in order to draw attention towards this rare, but equally severe side effect of cutaneous vasculitis due to the most commonly used drug for breast cancer. In view of the absence of alternative medications for pre-menopausal women, it is necessary to have a strict monitoring of its adverse effects as well as more intensive research for a better agent.

UR - http://www.scopus.com/inward/record.url?scp=85070353141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070353141&partnerID=8YFLogxK

U2 - 10.1177/1078155219862342

DO - 10.1177/1078155219862342

M3 - Article

AN - SCOPUS:85070353141

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

ER -